BioSight
Companies
Alto Neuroscience, Inc. logo

ANRO

NYSEMOUNTAIN VIEW, CA
Alto Neuroscience, Inc.

Alto Neuroscience develops drug candidates for neurological and psychiatric disorders using biomarker-based approaches to identify patient populations likely to respond to treatment. The company is in clinical development stage, conducting trials for multiple product candidates across psychiatry and neurology. Alto's strategy relies on identifying and validating biomarkers to predict treatment outcomes and improve the likelihood of clinical success.

Price history not yet available for ANRO.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar